top of page

BackTable / VI / Contributor

Dr. Terence Gade on the BackTable VI Podcast

Dr. Terence Gade

Interventional Radiologist

Dr. Terence Gade is a practicing interventional radiologist with at the University of Pennsylvania.

Listen to Dr. Terence Gade on the BackTable VI Podcast

The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Terence Gade and get practical advice on how to build your practice by listening to the BackTable VI Podcast.

Ep 402 Immunotherapy in HCC: Evolving Treatment Paradigms with Dr. Tyler Sandow, Dr. Edward Kim and Dr. Terence Gade
00:00 / 01:04

Stay Up To Date

Follow:

Subscribe:

Sign Up:

About Dr. Terence Gade

Terence P. Gade, MD, PHD graduated from medical school at the New York-Presbyterian / Weill Cornell Medical Center. He completed residency at the Hospital of the University of Pennsylvania and Lankenau Hospital and fellowship at the Hospital of the University of Pennsylvania. He is a Co-Director of the Penn Image-Guided Interventions (PIGI) Laboratory, an Assistant Professor of Radiology, and an Assistant Professor of Cancer Biology at the University of Pennsylvania. He is board certified in Diagnostic Radiology.

He also received his PhD in Biophysics from the Weill Graduate School of Medical Sciences of Cornell University and continues to conduct research.

He is a member of the following: Academy of Radiology Research (National), American Association for Cancer Research (National), American Society of Clinical Oncology (National), Association of University Radiologists (National), National Institutes of Health (National), Radiological Society of North America (International), Society of Interventional Oncology (International), and Society of Interventional Radiology (International).

Learn more by visiting Dr. Terence Gade's practice:

Podcasts Featuring Dr. Terence Gade

Episode #402

VI

In this episode, Dr. Tyler Sandow (Ochsner Health) interviews interventional radiologists Dr. Edward Kim (Mount Sinai) and Dr. Terence Gade (University of Pennsylvania) about the future directions of hepatocellular carcinoma (HCC) treatments, specifically focusing on the adoption of precision medicine and multidisciplinary approaches.

Episode #76

VI

Interventional Radiologist Terence Gade from Penn Medicine, University of Pennsylvania Health System tells us about emerging research and therapies targeting the tumor microenvironment in Hepatocellular carcinoma (HCC).

Episode #20

VI

Our 20th BackTable podcast episode featuring special guests Dr. Justin Lee of Florida Interventional Specialists, and Dr. Terence Gade of Hospital of University of Pennsylvania. They discuss experiences and utility of pressure-directed, antireflux infusion for TACE treatments.

Articles Featuring Dr. Terence Gade

Current Practices In Combination Therapy for Hepatocellular Carcinoma

Numerous systemic therapies, such as immunotherapy, can be utilized either with or without local therapy to treat hepatocellular carcinoma (HCC). Learn more about combination therapies and current practices.

An Introduction to Systemic Therapies for Hepatocellular Carcinoma

Interventional radiologists Dr. Edward Kim and Dr. Terence Gade explain the numerous systemic therapies, such as immunotherapy, used to treat hepatocellular carcinoma (HCC) with or without local regional therapy.

Surefire infusion catheter for pressure directed therapy

Effective drug delivery systems attempt to maximize homogeneous distribution of the respective agent to the entire tumor to induce cytotoxicity and tumor necrosis. Dr. Justin Lee and Dr. Terence Gade discuss how pressure-directed therapy improves drug delivery to areas of tumor burden in cases of HCC.

3D image of hepatocellular carcinoma

For the treatment of HCC, it is important to know the differences between DEB-TACE vs conventional TACE. Lipiodol-based conventional transarterial chemoembolization (cTACE) and drug-eluting bead transarterial chemoembolization (DEB-TACE) are two treatment options for intermediate-stage HCC.

TACE used to treat hepatocellular carcinoma

Transarterial chemoembolization (TACE) and radioembolization (Y90) have individualized roles in the treatment of hepatocellular carcinoma. Learn which patients are best suited for TACE vs Y90, as well as the pros and cons for each intervention.

Get Connected

Thank you for listening! If you have a question for Dr. Terence Gade about a topic discussed on the BackTable VI Podcast, you can get in touch with this form. Please note that our contributors are not able to respond to every inquiry.

Select which show(s) you would like to subscribe to:

Thanks! Message sent.

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

backtable-plus-vi-cta.jpg

Podcasts

Immunotherapy in HCC: Evolving Treatment Paradigms with Dr. Tyler Sandow, Dr. Edward Kim and Dr. Terence Gade on the BackTable VI Podcast)
Targeting the Tumor Microenvironment in HCC with Dr. Terence Gade on the BackTable VI Podcast)
Pressure-Directed Therapy in TACE with Dr. Justin Lee and Dr. Terence Gade on the BackTable VI Podcast)
Iliofemoral Stenting: Decision-Making & Best Practices Explored with Dr. Kush Desai and Dr. Steven Abramowitz on the BackTable VI Podcast)

Topics

Hepatocellular Carcinoma Condition Overview

More Contributors

Dr. Michael Barraza on the BackTable VI Podcast

Dr. Michael Barraza

Dr. Christopher Beck on the BackTable VI Podcast

Dr. Christopher Beck

Dr. Jennifer Berumen on the BackTable VI Podcast

Dr. Jennifer Berumen

Dr. Nicholas Fidelman on the BackTable VI Podcast

Dr. Nicholas Fidelman

Dr. Juan Gimenez on the BackTable VI Podcast

Dr. Juan Gimenez

Dr. Eric J. Keller on the BackTable VI Podcast

Dr. Eric J. Keller

bottom of page